Next generation sequencing (NGS) technologies are having a profound impact in basic and applied research, in manufacturing processes and in clinical applications. The ability to sequence whole genomes with relative ease has enabled the replacement of multiple individual molecular assays with a global detection methodology that can detect and characterize nucleic acids in any sample with high sensitivity and resolution. Powerful applications based on the easy detection of organisms in supposedly sterile preparations, characterizing cancer mutations from a solid tumor anywhere in the body by sequencing circulating tumor DNA in blood plasma or body fluids, or defining the list of organisms in an environment such as bovine rumen have become relatively trivial. In this journal supplement, the primary technologies used in NGS will be described and compared. Basic and translational applications of next generation sequencing will be delineated followed by a thorough description of key clinical applications. The instructors have more than a decade of experience in the development and deployment of NGS technologies.
Those interested in the following tracks:
Dr. Dawei Lin is the associate director for bioinformatics and the senior advisor to the Director of Division of Allergy, Immunology and Transplantation, NIAID, NIH. Prior to coming to NIH, Dr. Lin was the founding director of the Bioinformatics Core at the Genome Center, University of California, Davis. Before that, he played a key role in the modernization and operation of the Protein Data Bank (PDB) at Brookhaven National Laboratory. Dr. Lin is widely recognized for his contributions to various "Big Data" initiatives. Dr. Lin received his Ph.D. at Peking University, Beijing, China.
Dr. Lakdawalla is part of an angel group for genomics and health applications. He is running a liquid biopsy company and is an advisor for a 3rd gen sequencing tech. Previously, as a senior director at Thermo Fisher, he led infectious disease, reproductive health and ctDNA applications. At Illumina for seven years, he defined NGS systems and novel applications such as single cell, epigenomics and protein interactions. At Applied Biosystems, he led a technology incubator. At BioGenex, as technology director, he led the development of IHC and ISH products. He has a Ph.D. in Molecular Genetics from Bowling Green State University, Ohio, and a post-doc in Transgenics from the University of California, Berkeley.